A multicenter retrospective experience of infliximab in Crohn's disease patients: Infusion reaction rates and treatment persistency

Gastroenterology and Hepatology

Volumn 3, Issue 5, 2007, Pages 381-390

  Keshavarzian, Ali ^a   Mayer, Lloyd ^b   Salzberg, Bruce ^c   Garone, Michael ^d   Finkelslein, Warren ^e   Cappa, Joseph ^f   Brand, Myron ^g   Hain, Jon ^d   Zelinger, David ^h   Hegedus, Ronald ^h   Diamond, Robert H ^h   Campbell, Ulka ⁱ   Lane, Christi ^j   Stang, Paul ⁱ   Watson, John ⁱ   Cominelli, Fabio ^k  

^a RUSH UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Atlanta Gastroenterology Associates   (United States)

^d Gastroenterology Group of New Jersey ^*

^e Gastroenterology Group of New Jersey   (United States)

^f GI and Internal Medicine Associates   (United States)

^g Centocor Inc ^*  (United States)

^h CENTOCOR INC   (United States)

ⁱ Gait Associates   (United States)

^j University of Virginia Health System ^*  (United States)

^k UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

more..

Author keywords

Infliximab; Infusion reaction; Prophylaxis; Treatment persistency

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY;

EID: 34250648743     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sewitch JM, Abrahamowicz A, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544.
2. Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
5. Colombei JF, Loftus EV Jr, Termaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
6. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853.
7. Farrell RJ, Shall SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
8. Seiderer J, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort studv in 100 patients of a German University Hospital. Digestion. 2004;70:3-9.
9. Sample C, Bailey RJ, Todoruk D. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonron. Alberta. Can J Gastroenterol. 2002;16:165-170.
10. Farup PG, Hovde O, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995;30:164-170.
11. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut. 1990;30:179-183.
12. van Hees PA, van Tongcren JH. Compliance to therapy in patients on maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-336.
13. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
14. DiMatteo MR. Adherence to treatment. In: Feldman MD, Christensen JF, eds. Behavioral Medicine: A primary care handbook. New York: Appleton & Lange, 1997:136-140.
15. Cheifetz A, Smedly M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
16. 2 rest. J R Stat Soc. 1934;(suppl)1:217-235.
17. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 1. Lyon, France: International Agency for Research on Cancer; 1980.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplere observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
20. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic options. Inflamm Bowel Dis. 2006;12(suppl 1):S3-S9.
21. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60.
22. Remicade (infliximab) for IV injection [package insert]. Malvern, Pa: Centocor; 2006.
23. Lee GH, Benner D, Regidor DL, et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Renal Nutr. 2007;17:38-44.
24. Kalantar-Zadeh K, Rigidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070-3080.
25. Schols AMWJ, Wesseling G, Kester ADM, et al. Dose dependent increased mortality in COPD patients treated with oral Glucocorticoids. Eur Respir J. 2001;17:337-342.
26. Washerman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31:1912-1917.
27. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
28. Cruyssen BV, Van Looy S, Wyns B, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activiry. Arthritis Res Ther. 2006;8: R112(doi: 10.1186/ar2001).
29. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Gastroenterol Hepatol. 2003;15:1275-1280.
30. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
31. Kane S, Dixon L. Adherence rates with infliximab thetapy in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1099-1103.
32. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol. 2004;11:e267-e273.
33. Conlin PR, Gerth WO Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist iosartan versus other antihypertensive drug classes. Clin Therap. 2003;23:1999-2010.
34. Erkens JA, Panneman MMJ, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14:795-803.
35. Cramer JA. A systematic teview of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224.
36. Gold DT, Simon JA, Amonkar MM, et al. Tteatment persistence is improved with one-weekly versus once-daily bisphosphonate therapy, but remains suboptimal. Presented at the Sixth International Symposium on Osteoporosis, Washington DC, April 6, 2005. Poster.
37. Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs. one-weekly alendronate: results from the PERSIST study. Int J Clin Prac. 2006;60;896-905.
38. Sicras A, Rejas-Gutierrez J. Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine [in Spanish]. Rev Neurol. 2004;39:332-316.